

Alberto Sanchez-Fueyo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6375124/publications.pdf>

Version: 2024-02-01

68
papers

4,305
citations

145106

33
h-index

145109

60
g-index

70
all docs

70
docs citations

70
times ranked

4771
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers of Operational Tolerance After Liver Transplantation: Are We There Yet?. Liver Transplantation, 2022, 28, 15-16.	1.3	0
2	The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. American Journal of Transplantation, 2022, 22, 909-926.	2.6	4
3	Impact of donor extracellular vesicle release on recipient cell "cross-dressing" following clinical liver and kidney transplantation. American Journal of Transplantation, 2021, 21, 2387-2398.	2.6	25
4	On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation. American Journal of Transplantation, 2021, 21, 247-257.	2.6	8
5	Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. Hepatology, 2021, 73, 1985-2004.	3.6	57
6	On minor histocompatibility antigens, mixed chimerism, and transplantation tolerance. American Journal of Transplantation, 2021, 21, 919-920.	2.6	2
7	The Importance of Bringing Transplantation Tolerance to the Clinic. Transplantation, 2021, 105, 935-940.	0.5	3
8	Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. American Journal of Transplantation, 2021, 21, 2833-2845.	2.6	27
9	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. Journal of Hepatology, 2021, 75, 1409-1419.	1.8	31
10	Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?. European Journal of Immunology, 2021, 51, 2373-2386.	1.6	6
11	Prospects for Immune Tolerance. , 2021, , 442-454.		0
12	Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. American Journal of Transplantation, 2020, 20, 1125-1136.	2.6	139
13	Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. Hepatology, 2020, 72, 569-583.	3.6	45
14	Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 719-739.	8.2	62
15	Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation"Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. American Journal of Transplantation, 2020, 20, 2305-2317.	2.6	119
16	The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. American Journal of Transplantation, 2020, 20, 2156-2172.	2.6	30
17	Donor-specific antibodies in liver transplantation. GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 34-45.	0.0	0
18	Donor-specific antibodies in liver transplantation. GastroenterologÃa Y HepatologÃa, 2020, 43, 34-45.	0.2	19

#	ARTICLE	IF	CITATIONS
19	Extracellular vesicles as mediators of alloimmunity and their therapeutic potential in liver transplantation. <i>World Journal of Transplantation</i> , 2020, 10, 330-344.	0.6	8
20	Immune Tolerance After Liver Transplantation. , 2019, , 625-652.		4
21	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. <i>BMJ Open</i> , 2019, 9, e023518.	0.8	27
22	IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft survival. <i>American Journal of Transplantation</i> , 2019, 19, 2092-2100.	2.6	33
23	Normothermic Machine Perfusion (NMP) Inhibits Proinflammatory Responses in the Liver and Promotes Regeneration. <i>Hepatology</i> , 2019, 70, 682-695.	3.6	107
24	Histopathology of 460 liver allografts removed at retransplantation: A shift in disease patterns over 27 years. <i>Clinical Transplantation</i> , 2018, 32, e13227.	0.8	20
25	Biomarkers of immune tolerance in liver transplantation. <i>Human Immunology</i> , 2018, 79, 388-394.	1.2	35
26	Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis. <i>Hepatology</i> , 2018, 68, 1649-1652.	3.6	57
27	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 626-634.	1.8	46
28	Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. <i>Gastroenterology</i> , 2018, 155, 1838-1851.e7.	0.6	125
29	Multiparametric Analysis of Circulating Exosomes and Other Small Extracellular Vesicles by Advanced Imaging Flow Cytometry. <i>Frontiers in Immunology</i> , 2018, 9, 1583.	2.2	108
30	Can immunosuppression be stopped after liver transplantation?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 531-537.	3.7	32
31	IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7083-7088.	3.3	87
32	Immunotolerance in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2017, 37, 095-108.	1.8	17
33	Regulatory T-cell therapy in liver transplantation. <i>Transplant International</i> , 2017, 30, 776-784.	0.8	29
34	Immunotherapy in liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 874-875.	1.8	7
35	Conversion to Mycophenolate Mofetil Monotherapy in Liver Recipients: Calcineurin Inhibitor Levels are Key. <i>Annals of Hepatology</i> , 2017, 16, 94-106.	0.6	5
36	Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. <i>Oncotarget</i> , 2016, 7, 7563-7577.	0.8	126

#	ARTICLE	IF	CITATIONS
37	Strategies for minimizing immunosuppression: State of the Art. Liver Transplantation, 2016, 22, 68-70.	1.3	8
38	Peripheral phenotype and gene expression profiles of combined liver-kidney transplant patients. Liver International, 2016, 36, 401-409.	1.9	7
39	Biomarkers and immunopathology of tolerance. Current Opinion in Organ Transplantation, 2016, 21, 81-87.	0.8	15
40	Emergent Transcriptomic Technologies and Their Role in the Discovery of Biomarkers of Liver Transplant Tolerance. Frontiers in Immunology, 2015, 6, 304.	2.2	10
41	A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney International, 2015, 87, 984-995.	2.6	79
42	From immunosuppression to tolerance. Journal of Hepatology, 2015, 62, S170-S185.	1.8	133
43	Iron Deficiency Impairs Intra-Hepatic Lymphocyte Mediated Immune Response. PLoS ONE, 2015, 10, e0136106.	1.1	44
44	Dual transplantation-the immunological role of the liver. Nature Reviews Nephrology, 2014, 10, 364-365.	4.1	0
45	Immunosuppression withdrawal following liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 676-680.	0.7	14
46	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. Science Translational Medicine, 2014, 6, 242ra81.	5.8	74
47	Postoperative Monitoring: Biomarkers and Alloimmune Responses and Their Relevance to Vascularized Composite Allotransplantation. Current Transplantation Reports, 2014, 1, 203-210.	0.9	0
48	Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. Journal of Hepatology, 2013, 59, 872-879.	1.8	97
49	Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology, 2013, 58, 1824-1835.	3.6	269
50	Tolerance profiles and immunosuppression. Liver Transplantation, 2013, 19, S44-S48.	1.3	14
51	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. Journal of Clinical Investigation, 2012, 122, 368-382.	3.9	183
52	Immunologic Basis of Graft Rejection and Tolerance Following Transplantation of Liver or Other Solid Organs. Gastroenterology, 2011, 140, 51-64.e2.	0.6	195
53	Hot-topic debate on tolerance: Immunosuppression withdrawal. Liver Transplantation, 2011, 17, S69-S73.	1.3	42
54	The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: The updated follow up at 78 months. Transplant Immunology, 2008, 20, 43-47.	0.6	73

#	ARTICLE	IF	CITATIONS
55	Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. <i>Journal of Clinical Investigation</i> , 2008, 118, 2845-57.	3.9	249
56	Influence of direct and indirect allorecognition pathways on CD4+CD25+regulatory T-cell function in transplantation. <i>Transplant International</i> , 2007, 20, 534-541.	0.8	43
57	Specificity of CD4+CD25+ Regulatory T Cell Function in Alloimmunity. <i>Journal of Immunology</i> , 2006, 176, 329-334.	0.4	116
58	Roles of Deletion and Regulation in Creating Mixed Chimerism and Allograft Tolerance Using a Nonlymphoablative Irradiation-Free Protocol. <i>Journal of Immunology</i> , 2005, 175, 51-60.	0.4	69
59	Immunological tolerance and liver transplantation. <i>Journal of Hepatology</i> , 2004, 41, 698-705.	1.8	34
60	Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. <i>Nature Immunology</i> , 2003, 4, 1093-1101.	7.0	630
61	Tracking the Immunoregulatory Mechanisms Active During Allograft Tolerance. <i>Journal of Immunology</i> , 2002, 168, 2274-2281.	0.4	170
62	The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression.. <i>Transplantation</i> , 2002, 74, 898-900.	0.5	26
63	IMPACT OF THE RECURRENCE OF HEPATITIS C VIRUS INFECTION AFTER LIVER TRANSPLANTATION ON THE LONG-TERM VIABILITY OF THE GRAFT1. <i>Transplantation</i> , 2002, 73, 56-63.	0.5	153
64	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , 2001, 65, 35-44.	2.5	27
65	Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2001, 65, 266-275.	2.5	34
66	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. <i>Hepatology</i> , 2001, 34, 158-167.	3.6	44
67	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. , 2001, 65, 35.		2
68	Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. , 0, .		1